These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35830198)
1. Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs. Jones CM; Compton WM; Han B; Baldwin G; Volkow ND JAMA Psychiatry; 2022 Sep; 79(9):932-934. PubMed ID: 35830198 [TBL] [Abstract][Full Text] [Related]
2. Medicines for Patients After an Opioid Overdose. Ann Intern Med; 2018 Aug; 169(3):. PubMed ID: 29913484 [No Abstract] [Full Text] [Related]
3. History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020. Hallowell BD; Weidele HR; Daly M; Chambers LC; Scagos RP; Gargano L; McDonald J Am J Public Health; 2021 Sep; 111(9):1600-1603. PubMed ID: 34410818 [TBL] [Abstract][Full Text] [Related]
4. Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic. Kleinman RA; Sanches M Drug Alcohol Depend; 2023 Jan; 242():109703. PubMed ID: 36516551 [TBL] [Abstract][Full Text] [Related]
6. Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis. Anwar T; Duever M; Jayawardhana J Drug Alcohol Depend; 2022 Sep; 238():109565. PubMed ID: 35839618 [TBL] [Abstract][Full Text] [Related]
7. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. Brothers S; Viera A; Heimer R J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303 [TBL] [Abstract][Full Text] [Related]
8. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study. Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434 [TBL] [Abstract][Full Text] [Related]
9. Comparing methadone policy and practice in France and the US: Implications for US policy reform. Englander H; Chappuy M; Krawczyck N; Bratberg J; Potee R; Jauffret-Roustide M; Rolland B Int J Drug Policy; 2024 Jul; 129():104487. PubMed ID: 38878588 [TBL] [Abstract][Full Text] [Related]
10. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19. Roy V; Buonora M; Simon C; Dooling B; Joudrey P Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861 [TBL] [Abstract][Full Text] [Related]
11. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership. Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636 [No Abstract] [Full Text] [Related]
12. Racial, Ethnic, and Sex Differences in Methadone-Involved Overdose Deaths Before and After the US Federal Policy Change Expanding Take-home Methadone Doses. Harris RA; Long JA; Bao Y; Mandell DS JAMA Health Forum; 2023 Jun; 4(6):e231235. PubMed ID: 37294585 [TBL] [Abstract][Full Text] [Related]
13. Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model. Kleinman RA; Brothers TD; Danilewitz M; Bahji A J Addict Med; 2022 Sep-Oct 01; 16(5):499-504. PubMed ID: 35020695 [TBL] [Abstract][Full Text] [Related]
14. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment. Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469 [No Abstract] [Full Text] [Related]
15. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Krawczyk N; Mojtabai R; Stuart EA; Fingerhood M; Agus D; Lyons BC; Weiner JP; Saloner B Addiction; 2020 Sep; 115(9):1683-1694. PubMed ID: 32096302 [TBL] [Abstract][Full Text] [Related]
16. Cannabis Use and Nonfatal Opioid Overdose among Patients Enrolled in Methadone Maintenance Treatment. Bryson WC; Morasco BJ; Cotton BP; Thielke SM Subst Use Misuse; 2021; 56(5):697-703. PubMed ID: 33749499 [TBL] [Abstract][Full Text] [Related]
17. Methadone overdose in patients following methadone mainte- nance treatment:A three years overview in the district of Bari (South-Italy). Favia M; Santoiemma I; Mita Q; Strisciullo G; Introna F; De Donno A Clin Ter; 2021 May; 172(3):247-249. PubMed ID: 33956046 [TBL] [Abstract][Full Text] [Related]
18. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394 [TBL] [Abstract][Full Text] [Related]
19. Methadone's Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction). Suen LW; Incze M; Simon C; Englander H; Bratberg J; Groves Scott G; Winograd R Subst Use Addctn J; 2024 Jul; 45(3):337-345. PubMed ID: 38804606 [TBL] [Abstract][Full Text] [Related]
20. State policy uptake does not require formal action: A comment on Nesoff et al. McIlveen JW; Hoffman KA; McCarty D Addiction; 2022 Aug; 117(8):2359-2360. PubMed ID: 35352422 [No Abstract] [Full Text] [Related] [Next] [New Search]